2nd Quarter - Report
WAXMAN STRATEGIES for MEDICINES360
A later version of this report replaces this one, so LegiList's totals use the current version instead. This page shows this version exactly as filed.
Firm
Client
Income
—
Expenses
—
No amount is shown when the filer reports less than $5,000 for the period, which the form does not ask them to state.
Versions of this report
Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.
| Filing | Filed | Amount | Counted |
|---|---|---|---|
| 2nd Quarter - Report (this page) | Jul 15, 2024 | — | Replaced |
| 2nd Quarter - Termination | Jul 15, 2024 | — | Yes |
What was lobbied
One issue area, each in the filer's own words, with who lobbied on it and where.
Health Issues HCR
Support for non-profit pharmaceutical manufacturers
| Lobbyist | Covered position, as disclosed |
|---|---|
| JEREMY SHARP | LA,Rep Capps 2001-05 PSM, Sen HELP Comm 2007-10 LD, Sen Dodd 2010 DAS for Leg, HHS, 2011-13 Counselor, HHS, 2013-14 Dep Commissioner for Policy, FDA 2015-17 |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.